Login / Signup

Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701.

Tomono KawaseHiroshi ImamuraMasahiro GotoYutaka KimuraShugo UedaJin MatsuyamaKazuhiro NishikawaNaotoshi SugimotoJunya FujitaTakao TamuraNorimasa FukushimaHisato KawakamiDaisuke SakaiYukinori KurokawaToshio ShimokawaTaroh Satoh
Published in: International journal of clinical oncology (2021)
There was no difference in OS between irinotecan and paclitaxel no in OS prolongation of S-1 combination therapy in second-line chemotherapy.
Keyphrases
  • phase ii study
  • combination therapy
  • locally advanced
  • open label
  • neoadjuvant chemotherapy
  • placebo controlled
  • rectal cancer
  • squamous cell carcinoma
  • double blind
  • radiation therapy
  • phase ii
  • clinical trial
  • phase iii